Drug intelligence / Profile preview

MERVLYSIS

Development stage: Preclinical
Lead developer: CZ BioMed
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

MERVLYSIS is a preclinical-stage oncolytic virus therapy being developed by CZ BioMed for the treatment of melanoma. It is part of the RVLYSIS platform, which consists of genetically engineered common cold-derived viruses, specifically based on the human Respiratory Syncytial Virus (RSV). The virus is engineered to selectively replicate in and kill tumor cells while sparing normal cells. Its mechanism of action involves inducing apoptosis in cancer cells and stimulating systemic anti-tumor immune responses. CZ BioMed aims to license this product candidate to pharmaceutical companies for further development.

Other names: RVLYSIS variant

Beyond the preview

Go deeper on MERVLYSIS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MERVLYSIS.

Explore the full profile